OrbiMed Advisors LLC, a director and 10%-plus owner of Braveheart Bio, Inc. (BRVE), disclosed an open-market purchase of 1,666,667 shares at $18.00 apiece, a cash outlay of $30,000,006.00, according to a Form 4 filed with the SEC. The transaction is dated August 7, 2026, and brings OrbiMed’s indirectly held stake to 11,901,826 shares.
The purchase was made through an entity structure rather than directly in OrbiMed’s own name, which is typical for institutional holders that route trading activity through affiliated funds or investment vehicles. The filing lists the position as held indirectly, meaning the shares sit with a trust or fund entity tied to OrbiMed rather than the firm’s personal account.
Part of a Same-Day Buying Pattern
What stands out here is not just the size of the single purchase but its timing. OrbiMed’s buy is one of two open-market purchases of Braveheart Bio stock recorded on the same date, August 7, 2026, with the pair totaling $34,920,000 in combined value. Multiple insiders committing capital to the same stock on the same day is the kind of pattern our classification system flags as a cluster buy, a signal distinct from a single insider making an isolated trade.
The other side of that cluster was previously covered on this site, where Forbion put roughly $34.6 million into BRVE shares around the same window. Readers can find the details in our earlier report, Forbion Buys $34.6M of Braveheart Bio (BRVE) Stock, which covers that transaction in full.
Academic research on insider trading disclosures has generally found that clustered buying, where more than one insider purchases shares independently around the same time, tends to correlate with better subsequent stock performance than single, isolated purchases. That correlation is a statistical pattern observed across large datasets of filings, not a prediction about any individual company, and it does not account for company-specific risks or the broader market environment surrounding Braveheart Bio.
Form 4 filings disclose transactions made by officers, directors, and large shareholders, and they are a standard part of SEC reporting requirements rather than an indication of a company’s future direction. This report is based solely on the details disclosed in the filing and reflects only what has been made public about OrbiMed’s and Forbion’s respective transactions in Braveheart Bio stock on August 7, 2026.
→ See all BRVE coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.